Amyotrophic Lateral Sclerosis – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of amyotrophic lateral sclerosis (ALS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of ALS for each country, as well as annualized case counts projected to the national population.

Populations are forecast over a period of 20 years for the major mature pharmaceutical markets.

Clarivate Epidemiology’s ALS forecast will answer the following questions:

• How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of ALS?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of ALS over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 15 ALS patient populations, as follows:

• Diagnosed incident cases of (definite+probable+possible) ALS.
• Diagnosed incident cases of (definite) ALS.
• Diagnosed incident cases of (probable) ALS.
• Diagnosed incident cases of (possible) ALS.
• Diagnosed prevalent cases of (definite+probable+possible) ALS.
• Diagnosed prevalent cases of (definite) ALS.
• Diagnosed prevalent cases of (probable) ALS.
• Diagnosed prevalent cases of (possible) ALS.
• Diagnosed prevalent cases of familial ALS.
• Diagnosed prevalent cases of sporadic ALS.
• Diagnosed prevalent cases of ALS with Alzheimer’s disease.
• Diagnosed prevalent cases of ALS with dementia.
• Diagnosed prevalent cases of ALS with epilepsy.
• Diagnosed prevalent cases of ALS with frontotemporal dementia.
• Diagnosed prevalent cases of ALS with Parkinson’s disease.

Note: Coverage may vary by country.